[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spectroscopic-analysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spectroscopic-analysis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100639681","screening-characterization-and-longitudinal-follow-up-of-patients-with-cardiac-amyloidosis-100639681",false,"NCT07577466","Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis","Inclusion Criteria:\n\n* Age \\> 18 years\n* Male and female patients undergoing clinically indicated diagnostic work-up for amyloidosis or with a previously confirmed diagnosis of cardiac amyloidosis prior to initiation of therapy\n* Presence of left ventricular wall thickness \\> 12 mm on transthoracic echocardiography and at least one \"red flag\" suggestive of cardiac amyloidosis (according to ESC 2021 criteria) or an otherwise clinically established suspicion of amyloidosis\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Contraindications to cardiac MRI (e.g., metallic foreign bodies, older-generation pacemakers, severe obesity, claustrophobia)\n* Lack of written informed consent for study participation\n* Inability to comply with the study procedures","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","OBSERVATIONAL","Cardiac amyloidosis is a progressive disorder caused by extracellular deposition of amyloid fibrils in the heart, leading to heart failure and impaired cardiac function. Early diagnosis and targeted therapies are essential to improve patient outcomes. This prospective, single-center study aims to longitudinally follow patients with suspected cardiac amyloidosis to characterize disease progression and assess treatment effects. Participants will undergo cardiac magnetic resonance imaging (resting and exercise stress MRI), magnetic resonance spectroscopy, cardiopulmonary exercise testing (spiroergometry) and blood testing at baseline and at 6, 12, and 24 months",[23,24,25,26,27,28],"Amyloidosis Cardiac","Heart Failure","Cardiac MRI","Spectroscopic Analysis","Diagnosis","Phenotyping",[25,30,31,32,33,34,35,36],"Exercise MRI","Magnetic Resonace Spectroscopy","Spirometry","Cardiopulmonary Exercise Testing","Disease Progression","Treatment Monitoring","Longitudinal Study","NOT_YET_RECRUITING","2026-05-04",{"date":40,"type":41},"2026-05-11","ACTUAL",{"date":43,"type":19},"2026-06-15",{"date":45,"type":19},"2029-12-31",{"name":47,"class":48},"Heinrich-Heine University, Duesseldorf","OTHER"]